Compare SYSCO Corporation (SYY) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SYSCO Corporation vs Vertex Pharmaceuticals Incorporated — how do they compare? SYSCO Corporation trades at $78.03 (market cap $38.47B), while Vertex Pharmaceuticals Incorporated trades at $513.62 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 3.3× SYSCO Corporation's market cap, and SYSCO Corporation pays a 2.81% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold SYSCO Corporation for 77 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| SYY | VRTX | |
|---|---|---|
Market Cap | $38.47B | $127.55B |
Volume | 4,808,465 | 1,487,944 |
Sector | Consumer Staples | Health |
52-Week High | $91.16 | $557.96 |
52-Week Low | $69.30 | $407.37 |
Typical Hold Time | 77 Days | 120 Days |
Enterprise Value | $51.65B | $121.68B |
Dividend Yield | 2.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sysco Corporation (SYY) trades at $76.79, down 0.85% with a bearish technical outlook. The company shows solid revenue growth to $81.37B in 2025 but faces margin compression with net income margin at 2.08%. Recent developments include a $500M AI efficiency program and a $1.5B senior notes offering. Analyst consensus remains positive with 60% buy ratings and an $85.75 price target, representing 11.7% upside potential.
SYY offers value with a P/S ratio of 0.44x and dividend yield support, but faces execution risks on margin improvement and debt management. The stock trades below analyst targets, providing potential upside if the company delivers on its AI efficiency goals and maintains market leadership in food distribution.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
